BioTelemetry, Inc. (formerly CardioNet, Inc.) and Braemar Manufacturing, LLC Triumph in High-Stakes Patent Litigation Concerning Cardiac Monitors

In The News
February 3, 2014

A Ropes & Gray IP Litigation team has achieved a significant victory for clients BioTelemetry Inc. (formerly CardioNet) and Braemar (together, “BioTelemetry”) in a five-patent infringement suit against defendants Mednet Healthcare Technologies, Inc., Heartcare Corporation of America, Universal Medical Inc., and Universal Medical Laboratory, Inc. (“Mednet”) and its customers.

Days before the start of a jury trial in Philadelphia’s federal court, a consent judgment was entered by the court in which the court declared that the Mednet entities infringe all five asserted U.S. patents owned by BioTelemetry, all five patents are valid and enforceable, and that all defendants are enjoined from future infringing activities. 

The lawsuit, which was filed in the U.S. District Court for the Eastern District of Pennsylvania in May 2012, centered around patented technology used in BioTelemetry’s flagship product, the CardioNet MCOT system, a next-generation ambulatory cardiac monitoring service with beat-to-beat, real-time analysis, automatic arrhythmia detection, and wireless ECG transmission. The consent judgment is the culmination of almost two years of litigation between the two sides, including the court’s claim construction decision in which Biotelemetry prevailed on key disputed claim terms, and oral arguments on 24 substantive motions within a two-week period before trial.

Named 2014 Law Firm of the Year in Patent Litigation by U.S. News—Best Lawyers, Ropes & Gray’s IP litigation trial team is consistently recognized as a leader by national and global publications, including Chambers, Benchmark Litigation, International Asset Management and Managing IP. The Financial Times also recently recognized Ropes & Gray’s IP team as a “standout” firm for its “Lawyers to the Innovators” category, which selects leading firms that guide their clients toward innovation.